Physician profile
Amber Mohlman
NPI 1871289280
$5,238.58
in general payments reported to CMS, 2019-2025
27 companies · $3,297 in 2025
The $3,297 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $216 · 2024: $1,725 · 2025: $3,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,079 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,078.64 |
| Education | $159.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $665.74 | 2024-2025 | |
| Janssen Biotech, INC. | $551.22 | 2024-2025 | Tremfya |
| Ucb, INC. | $445.90 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $371.31 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $342.25 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $288.05 | 2023-2025 | |
| Leo Pharma INC. | $286.65 | 2024-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $282.33 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $276.41 | 2024-2025 | |
| Botanix Sb INC | $255.74 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $192.16 | 2024-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $152.88 | 2024-2025 | |
| Incyte Corporation | $152.18 | 2024-2025 | Opzelura, Opzelura |
| Amgen INC. | $137.39 | 2023-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $129.40 | 2024-2025 | Jublia, Cabtreo, Siliq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $128.25 | 2024-2025 | Nemluvio, Aklief |
| Almirall LLC | $123.20 | 2024-2025 | Klisyri, Seysara |
| Pfizer INC. | $94.87 | 2025 | |
| Dermavant Sciences, INC. | $76.89 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $58.37 | 2024-2025 | Zoryve |
| Journey Medical Corporation | $48.72 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $45.68 | 2025 | Oxistat |
| Organon LLC | $32.67 | 2025 | |
| Verrica Pharmaceuticals INC. | $30.69 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.09 | 2024 | Spevigo |
| Biofrontera INC. | $23.86 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Lnhc, INC | $21.68 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Mohlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.